ANRO250117P22500
- 0.00
- 0.000.00%
Alto Neuroscience Newsroom
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
JonesTrading Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $18
Alto Neuroscience Highlights Data From Precision Psychiatry Platform At ACNP Annual Meeting; Interim Analysis For ALTO-300 Phase 2b Trial In MDD Expected Q1 2025, With Topline Results In H1 2025
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Potential Catalysts and Strategic Focus: Analyzing Alto Neuroscience's Upcoming Trials and Precision Psychiatry Approach
Alto Neuroscience Strengthens Financial Position Amid Increased R&D
Alto Neuroscience Analyst Ratings
Stifel Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $10
Express News | Alto Neuroscience Inc : Stifel Cuts Target Price to $10 From $32
TD Cowen Maintains Alto Neuroscience(ANRO.US) With Buy Rating
Alto Neuroscience Cash Position Also Expected to Fund at Least Four Additional Clinical Study Readouts >ANRO
Alto Neuroscience 3Q Loss/Shr 62c >ANRO
Alto Neuroscience Q3 2024 GAAP EPS $(0.62) Beats $(0.65) Estimate
Alto Neuroscience | 10-Q: Q3 2024 Earnings Report
Alto Neuroscience | 8-K: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Express News | Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Press Release: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Alto Neuroscience to Participate in Upcoming Investor Conferences
Notable Analyst Calls This Week: McDonald's, Apple and Enphase Energy Among Top Picks
Wedbush Downgrades Alto Neuroscience to Neutral Following ALTO-100 Readout